Skin health and disease最新文献

{"title":"Prevalence and determinants of anxiety and depression in adult patients with atopic dermatitis in Tanzania.","authors":"Gloria E Masenga, Elisante J Masenga, Doriane Sabushimike, Kim Madundo, Lulyrita Kini, Jere A Mshana, Muzna Masoud, Janeth Mwase, Nelson Mosha, Aidan Mashuhuri, Agness B Kessy, Sylvia Kilenga, Peter Schmid-Grendelmeier, Alain Taieb, Ousmane Faye, Daudi R Mavura","doi":"10.1093/skinhd/vzag134","DOIUrl":"10.1093/skinhd/vzag134","url":null,"abstract":"<p><strong>Background: </strong>Atopic dermatitis (AD) is a chronic inflammatory skin disease increasingly associated with psychiatric co-morbidities, particularly anxiety and depression. Yet, evidence from sub-Saharan Africa remains scarce.</p><p><strong>Objectives: </strong>To determine the prevalence and associated factors of anxiety and depression among adult patients with AD in Northern Tanzania.</p><p><strong>Methods: </strong>A hospital-based cross-sectional study was conducted at the Regional Dermatology Training Centre (RDTC) between January 2022 and July 2023. AD was diagnosed using the Hanifin and Rajka criteria, and severity assessed with Scoring Atopic Dermatitis (SCORAD). Anxiety and depression were evaluated using the General Anxiety Disorder-7 and Patient Health Questionnaire-9 tools, respectively. Descriptive statistics and logistic regression were used to identify associations. <i>P</i>-values < 0.05 were considered statistically significant.</p><p><strong>Results: </strong>Overall, 241 adult patients with AD attending RDTC were enrolled, of whom 57.3% (<i>n</i> = 138/241) were women. The median age was 38 years (interquartile range 28-56). The prevalences of anxiety and depression were 41.5% and 30.3%, respectively. Anxiety was found to be associated with AD severity and cigarette smoking, while depression was significantly associated with female sex, age 40-59 years, occupation and AD severity.</p><p><strong>Conclusions: </strong>A considerable proportion of patients with AD in Tanzania experience psychological distress. Routine mental health screening and integrated multidisciplinary care are crucial in AD management, especially in low-resource settings.</p>","PeriodicalId":74804,"journal":{"name":"Skin health and disease","volume":"6 5","pages":"793-797"},"PeriodicalIF":0.0,"publicationDate":"2026-08-12","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC13623423/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"149083163","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Delayed cutaneous depigmentation in Vogt-Koyanagi-Harada disease.","authors":"Mohammed Shanshal, Sumbel Khan","doi":"10.1093/skinhd/vzag126","DOIUrl":"10.1093/skinhd/vzag126","url":null,"abstract":"<p><p>Vogt-Koyanagi-Harada disease may present to dermatologists through delayed integumentary findings after the acute ocular phase. This image-based case shows right frontotemporal depigmentation developing after bilateral panuveitis, with funduscopic changes compatible with convalescent disease.</p>","PeriodicalId":74804,"journal":{"name":"Skin health and disease","volume":"6 5","pages":"851-852"},"PeriodicalIF":0.0,"publicationDate":"2026-08-11","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC13623418/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"149083473","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Beyond diagnostic accuracy: evaluating the clinical utility of artificial intelligence for suspicious lesion triage.","authors":"Nethmi Chandrasekara","doi":"10.1093/skinhd/vzag129","DOIUrl":"10.1093/skinhd/vzag129","url":null,"abstract":"<p><p>The recent systematic review and meta-analysis by Nirula <i>et al</i>. reports pooled sensitivity and specificity of 89% and 82%, respectively, for artificial intelligence (AI)-based differentiation between benign and malignant skin lesions. This highlights the diagnostic potential of these tools. However, diagnostic accuracy alone does not establish clinical utility; a tool that performs well in retrospective validation may not meaningfully alter referral patterns, reduce waiting times or improve healthcare efficiency in practice. As we move closer to the implementation of AI technologies in dermatology services, future studies should evaluate implementation outcomes - including referral avoidance, biopsy rates and healthcare utilization - alongside traditional accuracy metrics.</p>","PeriodicalId":74804,"journal":{"name":"Skin health and disease","volume":"6 5","pages":"843-844"},"PeriodicalIF":0.0,"publicationDate":"2026-08-03","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC13623420/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"149083357","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Racial and ethnic disparities in T helper 2-mediated inflammatory skin disorders.","authors":"Bracha L Pollack, Arielle N Roberts, Benjamin D Wagner, Gopika Ashokan, Xizhao Chen, Geoffrey E Hespe, Jinyeon Shin, Annica R Stull-Lane, Sarit Pal, Babak J Mehrara, Raghu P Kataru","doi":"10.1093/skinhd/vzag124","DOIUrl":"10.1093/skinhd/vzag124","url":null,"abstract":"<p><p>T helper type 2 (Th2)-mediated inflammatory skin diseases, including atopic dermatitis, discoid lupus erythematosus, systemic sclerosis, autoimmune bullous diseases and secondary lymphoedema, demonstrate significant racial and ethnic disparities in prevalence, severity and clinical outcomes. These disorders share pathogenic mechanisms involving Th2-driven immune activation, fibrosis and epidermal barrier dysfunction, leading to chronic inflammation and substantial morbidity. Black and Hispanic populations consistently experience greater disease burden, more severe clinical manifestations and reduced quality of life compared with White patients, reflecting complex interactions between biologic and socioeconomic factors. Current molecular and immunological studies suggest that ancestry-associated differences in immune polarization, cytokine signalling, autoantibody expression, fibrotic pathways and epidermal barrier biology may contribute to variation in disease phenotype and severity across Th2-mediated disorders. Black patients have demonstrated enhanced Th2 and Th22-mediated inflammation, increased IgE production, elevated interleukin (IL)-4, IL-13 and IL-22 signalling, and distinct genetic and serological profiles, including variation in filaggrin-related barrier proteins and autoantibody expression. However, mechanistic studies directly evaluating race-associated Th2 immune responses remain limited in many inflammatory skin diseases, and under-representation of diverse populations in translational research and clinical trials continues to restrict understanding of disease biology and therapeutic response. This review synthesizes the current epidemiological, molecular and immunological evidence linking race, immune dysregulation and disease heterogeneity across Th2-mediated skin disorders. Together, these findings support a growing framework in which ancestry-associated differences in immune regulation and social determinants jointly shape disparities in Th2-mediated inflammatory skin disease.</p>","PeriodicalId":74804,"journal":{"name":"Skin health and disease","volume":"6 5","pages":"668-679"},"PeriodicalIF":0.0,"publicationDate":"2026-07-31","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC13623444/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"149083183","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Treatment adherence in acne vulgaris: systematic review and narrative synthesis.","authors":"Miriam Santer, Emma Maund, Taeko Becque, Rosie Essery, John S Barbieri, Beth Stuart, Tracey H Sach, Fathema Miah, Matthew J Ridd, William Price, Joanna Pang, Sophie Dove, Irene Soulsby, Kim S Thomas, Kate Henaghan-Sykes, Mary Steele, Steph Easton, Sebastien Pollet, Angel Umensofor, Sinéad M Langan, Nick A Francis, Andrew R Thompson, Paul Little, Alison M Layton, Ingrid Muller","doi":"10.1093/skinhd/vzag084","DOIUrl":"10.1093/skinhd/vzag084","url":null,"abstract":"<p><strong>Background: </strong>Acne vulgaris is common and has a substantial impact on patients' quality of life. Low adherence to acne treatments is a barrier to successful management.</p><p><strong>Objectives: </strong>To examine the prevalence of adherence to oral and topical treatments for acne, factors associated with adherence and reasons for nonadherence.</p><p><strong>Methods: </strong>We included primary quantitative studies that investigated acne-related experiences and behaviours, including predictors, determinants and outcomes associated with treatment adherence. We searched the following databases from inception until 24 March 2025, with no language restrictions: MEDLINE, PubMed, Embase, PsycINFO and CINAHL. Quality was appraised using the Mixed Methods Appraisal Tool. We present the findings related to observational studies, analysed using narrative synthesis.</p><p><strong>Results: </strong>Twenty-six eligible papers reported studies in the Americas, Europe and Asia. Thirteen papers reported quantitative descriptive studies (8111 survey participants plus 2 studies that reported data from electronic health records) and 13 papers (12 studies, 37 884 participants) reported other designs such as analytic cross-sectional or cohort studies. Methods for evaluating adherence varied: 21 studies used self-report with differing questionnaire designs, 3 used prescription data to evaluate medication possession ratio, 3 assessed drug refills, 1 carried out database drug survival analysis and 1 used pill count or tube weighing. Four studies used more than one method. The prevalence of adherence estimates varied from 6% to 84%, with larger studies estimating 50-65% adherence. Adherence was lower among younger people, but there was inconsistent evidence for differences between men and women, or between topical and oral treatments. Reasons for nonadherence included cost, side effects, perceived treatment ineffectiveness or symptom resolution.</p><p><strong>Conclusions: </strong>Improving treatment adherence in acne remains a priority, particularly for younger people. Interventions addressing the management of side effects and time to effectiveness of treatments may be beneficial.</p>","PeriodicalId":74804,"journal":{"name":"Skin health and disease","volume":"6 5","pages":"690-711"},"PeriodicalIF":0.0,"publicationDate":"2026-07-31","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC13623435/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"149083159","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Localized comedones and perifollicular hyperpigmentation during tapinarof cream therapy: a case series.","authors":"Yusuke Sano, Yasuaki Ogura, Hiroki Morimoto, Naoko Funai, Tetsuya Honda","doi":"10.1093/skinhd/vzag121","DOIUrl":"10.1093/skinhd/vzag121","url":null,"abstract":"<p><p>Tapinarof is an aryl hydrocarbon receptor agonist approved for the treatment of atopic dermatitis (AD) and psoriasis. While common adverse events include headache and folliculitis, comedones and perifollicular hyperpigmentation are under-recognized. Here, we report eight patients with AD or psoriasis who developed comedones and/or perifollicular hyperpigmentation during therapy. Lesions developed primarily at application sites; however, in one patient, lesions occurred at a distant site. Lesions appeared on the face in six patients, the legs in one and the arms in one. Time of onset ranged from 1 to 8 months after initiation of tapinarof therapy. Tapinarof was discontinued in all cases. Three patients were treated with topical adapalene/benzoyl peroxide, with partial improvement in one and minimal improvement in two. One patient showed gradual improvement without additional treatment, whereas the remaining five showed no or minimal improvement during follow-up. Our cases provide important information on under-recognized adverse events during tapinarof therapy.</p>","PeriodicalId":74804,"journal":{"name":"Skin health and disease","volume":"6 5","pages":"823-827"},"PeriodicalIF":0.0,"publicationDate":"2026-07-31","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC13623433/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"149082947","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Evaluating serum procollagen type III N-terminal peptide use as a liver fibrosis screening test in patients with psoriasis receiving methotrexate: a retrospective service evaluation in comparison with the Fibrosis-4 (FIB-4) index.","authors":"Gary Roulston, Conall McKinney, Maia Monaghan, Catriona McMullan, Kathryn Ryan, Derek McKillop, David Alderdice","doi":"10.1093/skinhd/vzag116","DOIUrl":"10.1093/skinhd/vzag116","url":null,"abstract":"<p><p>Whilst procollagen type III N-terminal peptide (PIIINP) is recommended as a marker of liver fibrosis in patients with psoriasis on methotrexate, its efficacy is increasingly questioned. PIIINP is not specific as a marker of liver fibrosis, is expensive and has a lengthy turnaround time. There is growing evidence that methotrexate is not a direct cause of liver disease. Fibrosis-4 (FIB-4) is a validated screening score of liver fibrosis that has a substantial weight of evidence. FIB-4 scores are quick to calculate, minimally invasive and cost-effective. Our study reviews PIIINP use versus FIB-4 use in patients with psoriasis about to start or taking methotrexate therapy. This service evaluation demonstrates poor real-world adherence to PIIINP monitoring guidance and a lack of correlation between PIIINP and FIB-4 referral thresholds.</p>","PeriodicalId":74804,"journal":{"name":"Skin health and disease","volume":"6 5","pages":"835-837"},"PeriodicalIF":0.0,"publicationDate":"2026-07-31","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC13623424/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"149082518","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Exploration of burnout and imposter phenomenon among dermatology resident doctors in the UK.","authors":"Honey Brandy Frimpong-Manso, Bisam-Ul Haq, Aparna Potluru, Rhianne Foley, Sidra Khan, Jonathan Guckian","doi":"10.1093/skinhd/vzag098","DOIUrl":"10.1093/skinhd/vzag098","url":null,"abstract":"<p><strong>Background: </strong>Dermatology training is highly competitive, yet UK-specific data on trainee wellbeing are limited. Burnout describes emotional exhaustion and reduced professional fulfilment due to chronic stress, while imposter phenomenon (IP) reflects persistent self-doubt despite objective competence.</p><p><strong>Objectives: </strong>To examine the prevalence and drivers of burnout and IP among UK dermatology registrars.</p><p><strong>Methods: </strong>A national questionnaire survey was distributed to UK dermatology trainees in May 2025. Burnout was assessed using the Emotional Exhaustion (EE) subscale of the Maslach Burnout Inventory, and IP using validated scales. Free-text responses explored drivers of burnout and IP and protective factors, and were analysed using inductive thematic analysis.</p><p><strong>Results: </strong>Eighty-four trainees responded [74% women (<i>n</i> = 62/84)]. Significant burnout (EE >13) was identified in 44% (<i>n</i> = 37/84). Trainees with -burnout reported significantly higher IP scores than those without (mean 26 vs. 22; <i>P</i> = 0.005). Burnout was strongly associated with poor work-life integration (<i>P</i> < 0.001) and thoughts of leaving the specialty [49% (<i>n</i> = 41/84) vs. 17% (<i>n</i> = 14/84); <i>P</i> = 0.001]. There were no significant differences between burnout groups by age, sex or ethnicity. Qualitative analysis identified five themes: unattainable targets (administrative workload and Specialty Certificate Examination pressure), disrupted transitions, feelings of abandonment due to limited supervision, competing priorities and professional identity violation.</p><p><strong>Conclusions: </strong>These novel UK data demonstrate that burnout and IP are common and closely related among dermatology registrars. Prevalence was comparable to that reported in international literature. Drivers appear to be predominantly structural rather than demographic, particularly administrative burden, high-stakes assessment and inconsistent access to support. System-level interventions, including protected self-development time and increased examination sittings, may help support the workforce. These findings provide an important baseline for future policy development and research into trainee wellbeing in UK dermatology.</p>","PeriodicalId":74804,"journal":{"name":"Skin health and disease","volume":"6 5","pages":"763-769"},"PeriodicalIF":0.0,"publicationDate":"2026-07-31","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC13623432/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"149083019","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Correction to: Pilar leiomyoma with dermatofibroma-like dermatoscopic features: a clinical challenge.","authors":"","doi":"10.1093/skinhd/vzag132","DOIUrl":"https://doi.org/10.1093/skinhd/vzag132","url":null,"abstract":"<p><p>[This corrects the article DOI: 10.1093/skinhd/vzag088.].</p>","PeriodicalId":74804,"journal":{"name":"Skin health and disease","volume":"6 5","pages":"856"},"PeriodicalIF":0.0,"publicationDate":"2026-07-29","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC13623415/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"149083491","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Identifying and addressing obstacles to optimal alopecia areata and atopic dermatitis care in the UK.","authors":"Stephanie Gallard, Sue Schilling, Suzi Holland, Megan Mowbray, Sophia Conner, Manjit Kaur, Yousaf Aftab, Benoit Raymond, Gulraj Matharu, Karim Amer, Kave Shams, Leila Asfour","doi":"10.1093/skinhd/vzag117","DOIUrl":"10.1093/skinhd/vzag117","url":null,"abstract":"<p><p>Alopecia areata (AA) and atopic dermatitis (AD) are both chronic inflammatory conditions, associated with physical and significant psychosocial burden, with patients facing considerable barriers to care in the UK. In this perspective, we explore gaps in care in the UK healthcare system for patients with AA and AD, gaining insights from healthcare professionals, patients and patient advocates to identify opportunities for improvement within primary care and secondary care.</p>","PeriodicalId":74804,"journal":{"name":"Skin health and disease","volume":"6 5","pages":"838-842"},"PeriodicalIF":0.0,"publicationDate":"2026-07-28","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC13623443/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"149082999","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}